Donated plasma serves as the raw material for a surprisingly wide range of medical treatments, from emergency transfusions during trauma to long-term therapies for rare genetic conditions. Once separated from whole blood or collected through a dedicated donation process, plasma can be transfused directly or broken down into specific proteins like immunoglobulins, clotting factors, and albumin. Each of these products fills a medical need that, in many cases, no synthetic drug can fully replace.
How Donated Plasma Becomes Medicine
Before plasma can treat anyone, it has to be processed. The dominant industrial method dates back to the 1940s and uses cold ethanol to precipitate different protein groups out of pooled plasma in stages, much like refining crude oil into its components.1PubMed Central. Implementation of Plasma Fractionation in Biological Medicines Production Each stage yields a different “fraction” rich in a particular protein. Modern facilities layer chromatography and other purification steps on top of this ethanol backbone to achieve higher purity and yield.2PubMed. The past, present and future of blood plasma fractionation The result is a family of distinct pharmaceutical products, each derived from the same liter of donated plasma: albumin, immunoglobulins, clotting factors, and several rarer specialty proteins.
Not all donated plasma goes through fractionation, though. Some is frozen within hours of collection and stored as fresh frozen plasma, or FFP, which retains nearly all of its original proteins in their natural ratios. FFP is used directly in hospitals, most often as a transfusion product during emergencies.
Fresh Frozen Plasma in Trauma and Surgery
When someone is bleeding massively from a car accident, a gunshot wound, or a surgical complication, they lose not just red blood cells but the clotting proteins dissolved in plasma. Replacing red cells alone without restoring those clotting factors can lead to a dangerous condition where the blood simply cannot form stable clots. FFP addresses this by supplying the full complement of coagulation proteins at once.
Trauma is one of the largest consumers of FFP in hospitals. Traditional guidelines called for checking lab results before giving plasma, but by the time results came back, patients were often already in full-blown coagulopathy. A shift in thinking over the past two decades led to what is sometimes called “damage-control resuscitation,” where FFP is given early and in a roughly equal ratio with red blood cell units. Retrospective studies have linked higher FFP-to-red-cell ratios during massive transfusion with improved initial survival, though interpreting that data is complicated by the fact that patients who survive long enough to receive more plasma are already a somewhat self-selected group.3PubMed. Fresh frozen plasma (FFP) use during massive blood transfusion in trauma resuscitation Despite those caveats, the early-and-aggressive approach to FFP in trauma has become mainstream practice in many trauma centers.4PubMed Central. Clinical review: Fresh frozen plasma in massive bleedings – more questions than answers
It is worth noting that audits have found roughly half the FFP transfused in critical care settings to be clinically inappropriate, meaning doctors sometimes reach for it when other products or no product would be better. This is a known quality-improvement challenge in hospitals, not a reflection on the plasma itself.4PubMed Central. Clinical review: Fresh frozen plasma in massive bleedings – more questions than answers
Immunoglobulin Therapies
Immunoglobulins, the antibodies your immune system produces, are one of the most valuable products extracted from donated plasma. They account for a large share of global plasma demand. Once purified, they are given intravenously (IVIg) or subcutaneously to patients whose own bodies cannot make enough antibodies or whose immune systems are attacking their own tissues.
The most straightforward use is replacement therapy for people born with primary immunodeficiency disorders. These individuals lack the normal repertoire of protective antibodies, leaving them vulnerable to repeated and sometimes life-threatening infections. Regular immunoglobulin infusions essentially borrow the collective immune memory of thousands of plasma donors, giving the patient a broad shield of antibodies they cannot produce on their own.5PubMed. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders
Immunoglobulin therapy also has a substantial role in neurology. In conditions like Guillain-Barré syndrome and myasthenia gravis, the immune system mistakenly attacks nerve tissue. IVIg can tamp down that misdirected immune response. A study of 141 patients treated for various neuroimmune conditions found that IVIg mostly led to neurological improvement in myasthenia gravis and Guillain-Barré, while in chronic inflammatory demyelinating polyneuropathy and neuromyelitis optica it more often stabilized the disease rather than reversing damage.6PubMed Central. Efficacy and Safety of Intravenous Immunoglobulin Treatment in Selected Neurological Diseases-One Centre’s Experience Based on the Therapy of 141 Patients The distinction matters for patients: in acute flare-ups, immunoglobulin can produce meaningful recovery, while in slower-burning chronic conditions, the goal shifts toward preventing further deterioration.
Hyperimmune Globulins for Specific Infections
Standard immunoglobulin pools contain a diverse mix of antibodies. But sometimes clinicians need a concentrated dose of antibodies against one particular pathogen. Hyperimmune globulins are manufactured by selecting plasma from donors with especially high levels of a specific antibody, then purifying that fraction. Products like these are available for preventing or treating infections caused by respiratory syncytial virus, cytomegalovirus, varicella-zoster virus, rabies, and tetanus.7PubMed Central. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases
A transplant patient exposed to cytomegalovirus, for example, might receive CMV-specific hyperimmune globulin to prevent the virus from taking hold while their immune system is suppressed. A person bitten by a potentially rabid animal receives rabies immunoglobulin alongside the vaccine to provide immediate protection while the vaccine primes a longer-term response. These products cannot be synthesized in a lab; they depend entirely on the immune histories of real donors.
Clotting Factor Replacement
Hemophilia A and B are genetic disorders in which patients lack specific clotting factors (factor VIII and factor IX, respectively). Before plasma-derived factor concentrates became available in the 1970s, hemophilia was a profoundly disabling and often fatal condition. The introduction of plasma-derived factor VIII concentrates dramatically improved life expectancy and quality of life.8PubMed Central. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better
That success was shadowed by tragedy in the 1980s, when contaminated plasma pools transmitted HIV and hepatitis to thousands of hemophilia patients worldwide. The crisis drove two parallel developments: rigorous pathogen-reduction steps for plasma-derived products and the creation of recombinant clotting factors manufactured using genetically engineered cell lines rather than human plasma. Today, recombinant products dominate hemophilia treatment in wealthy countries, but plasma-derived concentrates remain essential in much of the world where recombinant alternatives are unavailable or too expensive.
Beyond hemophilia, plasma-derived clotting products address other bleeding emergencies. Cryoprecipitate, a fraction of FFP rich in fibrinogen and factor XIII, is used to replenish fibrinogen in patients with severe traumatic bleeding. Early administration of cryoprecipitate has been shown to be both feasible and effective for fibrinogen replacement in major trauma.9PubMed. Targeted cryoprecipitate transfusion in severe traumatic haemorrhage Fibrinogen concentrate, a more purified product also derived from plasma, has been compared with cryoprecipitate in trauma settings, with some evidence suggesting it is associated with reduced need for other blood products and shorter hospital stays.10PubMed. Fibrinogen supplementation for the trauma patient: Should you choose fibrinogen concentrate over cryoprecipitate?
Albumin in Burns, Liver Disease, and Critical Care
Albumin is the most abundant protein in plasma, making up roughly half of the total protein content. Clinically, it serves as a volume expander, pulling fluid into the bloodstream through osmotic pressure, and it plays roles in transporting hormones, drugs, and other molecules. Plasma-derived albumin is one of the oldest and most widely used plasma products.
Burn patients are among the most prominent recipients. In major burns, fluid leaks out of damaged blood vessels at a massive rate, and resuscitation with crystalloid fluids alone can lead to dangerous fluid overload. Adding albumin to the resuscitation regimen has been linked to meaningful improvements in survival. A meta-analysis of controlled clinical studies found that albumin infusion was associated with substantially reduced mortality in burn patients, with a pooled odds ratio of about 0.34, meaning roughly a threefold reduction in the odds of death. The same analysis showed a significantly lower rate of compartment syndrome when albumin was used.11PubMed Central. Albumin in Burn Shock Resuscitation: A Meta-Analysis of Controlled Clinical Studies Human studies also suggest that incorporating albumin during acute burn resuscitation achieves adequate volume replacement with a lower total fluid requirement and better maintenance of blood volume and cardiac output, though there are trade-offs including possible increases in lung fluid in the first week.12PubMed. A review of the use of human albumin in burn patients
In liver disease, albumin plays a different role. Patients with advanced cirrhosis often develop ascites, fluid accumulation in the abdomen that periodically needs to be drained through a procedure called large-volume paracentesis. Albumin is given during the procedure to prevent circulatory complications.13PubMed Central. Low-Dose vs. Standard Care Iv Human Albumin During Large-Volume Paracentesis in Patients With Liver Cirrhosis: A Systematic Review Guidelines also recommend long-term albumin administration for patients with refractory ascites, where it can sometimes restore responsiveness to diuretic medications.14Journal of Hepatology. Long-term albumin treatment in decompensated cirrhosis
The evidence for albumin in cirrhosis is not uniformly positive, however. Preclinical work had suggested albumin could play an anti-inflammatory role in decompensated cirrhosis, raising hopes that aggressive albumin infusions might reduce infections, kidney failure, and death. A large randomized trial tested this by targeting a serum albumin level of 30 grams per liter or higher in hospitalized cirrhosis patients using repeated daily infusions of concentrated albumin. The result was essentially no difference in outcomes compared with standard care.15PubMed. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis So albumin has a clear role in specific scenarios like paracentesis and burn resuscitation, but attempts to use it more broadly as a general anti-inflammatory agent in cirrhosis have not panned out.
Rarer Plasma Proteins with Outsized Impact
Some plasma-derived therapies treat conditions that are uncommon individually but collectively affect hundreds of thousands of people. Two stand out for how directly they depend on donated plasma.
Alpha-1 Antitrypsin for Lung Disease
Alpha-1 antitrypsin deficiency is a genetic condition in which the liver produces too little of a protein that protects lung tissue from damage by enzymes released during normal immune activity. Without it, the lungs gradually break down, leading to emphysema, often at a young age. Augmentation therapy involves regular intravenous infusions of alpha-1 antitrypsin purified from donated plasma. The treatment restores the protein’s protective capacity in the lungs and reduces inflammatory activity there.16PubMed Central. Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential
The evidence for this therapy is nuanced. The largest randomized controlled trial showed a significant slowing in the rate of lung tissue loss, measured by CT scan density, in patients receiving augmentation therapy compared with placebo.17European Respiratory Review. Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint A Cochrane review confirmed that lung density deteriorated significantly less in treated patients.18PubMed Central. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease However, the therapy does not improve symptoms like breathlessness, exercise capacity, or quality-of-life scores, and data on whether it reduces mortality or hospital admissions remain sparse.17European Respiratory Review. Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint For patients, this means the treatment works more like a brake pedal than a repair kit: it slows the damage but does not reverse what has already happened.
C1 Inhibitor for Hereditary Angioedema
Hereditary angioedema is a condition caused by deficiency or dysfunction of C1 inhibitor, a plasma protein that regulates part of the complement and contact-activation systems. When C1 inhibitor is lacking, patients experience unpredictable episodes of severe swelling that can affect the face, hands, gut, and, dangerously, the airway. Plasma-derived C1 inhibitor concentrate treats acute attacks and can also be used preventively.
The clinical response can be dramatic. In controlled trials, symptoms began improving within about 30 minutes of infusion with C1 inhibitor concentrate, compared with an average of over nine hours for placebo. About 69% of attacks treated with the concentrate showed some improvement within half an hour, versus just 2% with placebo. Complete resolution of symptoms was also significantly faster in treated patients.19PubMed Central. Treatment of hereditary angioedema with plasma-derived C1 inhibitor The concentrate has also been established as effective for preventing attacks when used on a regular schedule, regardless of where on the body the swelling occurs.20PubMed Central. Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency Both children and adults receive this therapy.21The Journal of Allergy and Clinical Immunology: In Practice. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema—A Long-Term Survey
Convalescent Plasma in Pandemics and Emerging Infections
The idea of using plasma from recovered patients to treat those still sick is over a century old. In outbreaks where no vaccine or specific drug exists, convalescent plasma offers a way to transfer protective antibodies directly from survivors to patients who need them. This strategy gained renewed attention during the Ebola outbreak in West Africa and became a major research focus during COVID-19.22PubMed Central. Convalescent plasma: new evidence for an old therapeutic tool?
The COVID-19 experience produced mixed but instructive results. Early in the pandemic, convalescent plasma was used widely under emergency authorizations. A study of unvaccinated COVID-19 patients found that those treated with convalescent plasma had a 91% survival rate compared with about 83% in the control group, with roughly a twofold reduction in the risk of death after adjusting for age.23PubMed Central. Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients The benefit appeared to come through immune modulation rather than direct anti-inflammatory effects. As vaccines and antiviral drugs became available, convalescent plasma’s role narrowed, but the infrastructure built around collecting and distributing it remains a template for future pandemic responses.
How Plasma Products Are Made Safe
Given the history of blood-borne pathogen transmission through plasma products in the 1980s, safety processing is a critical part of modern plasma manufacturing. The dominant approach is solvent/detergent treatment, an industrial process that destroys the lipid envelopes surrounding viruses like HIV and hepatitis B and C. This method has been in use for about three decades and produces plasma products with an extremely high level of decontamination from transmissible agents.24PubMed Central. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience
Solvent/detergent treatment does have a gap: it does not affect non-enveloped viruses, which lack the lipid coat that the chemicals target. Infections from non-enveloped viruses like hepatitis A and parvovirus B19 are managed through a different set of strategies: screening individual donations for viral loads, pooling large numbers of units so that any single contaminated donation is heavily diluted, and relying on the neutralizing antibodies already present in the pooled plasma from thousands of donors.25PubMed Central. The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma More recently, the addition of prion-binding gels has addressed concerns about the prion proteins responsible for variant Creutzfeldt-Jakob disease, reducing abnormal prion protein by more than five orders of magnitude.25PubMed Central. The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma
Solvent/detergent-treated plasma also carries a practical bonus for transfusion medicine: the process removes or neutralizes the antibodies responsible for transfusion-related acute lung injury, one of the most dangerous complications of plasma transfusion.24PubMed Central. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience This makes it a standardized pharmaceutical product rather than a variable biological one, with consistent clotting factor content from batch to batch.
Why Plasma Cannot Easily Be Replaced by Synthetic Alternatives
A reasonable question is whether donated plasma will eventually be made obsolete by lab-manufactured alternatives. For some products, that transition is well underway: recombinant clotting factors have largely replaced plasma-derived ones for hemophilia in high-income countries, and monoclonal antibodies are entering the immunology space. But several factors keep donated plasma indispensable for the foreseeable future.
Immunoglobulin therapy is the biggest driver. Each batch of IVIg contains antibodies shaped by the real-world immune exposures of thousands of different people. That diversity is the point. Manufacturing a synthetic equivalent would mean replicating not just one antibody but an entire population’s immune repertoire, which no current technology can do at scale. For niche products like hyperimmune globulins, albumin for burns, and C1 inhibitor, the volumes needed are too small to attract the massive investment that recombinant manufacturing requires, and some of these proteins are difficult to produce in active form outside of human biology. Global demand for plasma-derived immunoglobulins continues to grow faster than supply, which is why donation programs remain a critical part of health infrastructure across the world.